Although the omega-3 fatty acids are essential for life, their bioavailability is low when delivered by oral route using traditional triglyceride forms of administration, especially for promoting brain functions [1-4]. Liposomes prepared from natural lipid mixtures extracted from marine animals appeared to be superior candidates for DHA/EPA supplementation. The greater bioavailability of omega-3 PUFAs measured after phospholipid liposome ingestion, compared with triglycerides ingestion, is supported by a number of animal and clinical studies [5-7].

A recent studies have been clearly pointed out that for the brain DHA donors, DHA carriers plays an important role, and it demonstrated that DHA - containing phosphatidylserine molecular species are, so far, the best transporters [5-6]; whereas the metabolic rule of DHA - containing phosphatidylserine is very different from soy-PS + DHA triglycerides, so called PS-DHA conjugated complex [4].

[1] A. Werner, R. Havinga, F. Kuipers, H. J. Verkade, Am. J. Physiol. Gastrointest Liver Physiol. 286 (2004) G822.
[2] M. Cansell, Lipid Technology 22 (2010) 223.
[3] A. Lamaziere, D. Ricjard, U. Barbe, K. Fefi, P. Bausero, Prostag. Leukotri. Ess. Fatty Acids 84 (2011) 7.
[4] B.A. Graf, G.S.M.J.E. Duchateau, A.B. Patterson, E.S. Mitchell, P. Van Bruggen, J.H. Hoek, Prostag. Leukotri. Ess.
　 Fatty Acids 83 (2010) 89.
[5] T. Ohkubo, Y. Tanaka, J. Oleo Sci. 59 (2010) 247.
[6] N. Vaisman, D. Pelled, Progress in Neuro-Psychopharmacology & Biological Psychiatry 33 (2009) 952.
[7] S.M. Ulven, B. Kirkhus, A. Lamglait, S. Basu, E. Blind, T. Haider, K. Berge, H. Vik, Jan I. Pedersen, Lipids 46 (2011)
　 37.